Cutera (NASDAQ:CUTR) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Cutera (NASDAQ:CUTR) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the medical device company’s stock.

Cutera Price Performance

CUTR opened at $0.04 on Thursday. The company has a 50 day simple moving average of $0.26 and a two-hundred day simple moving average of $0.42. The firm has a market cap of $787,254.00, a P/E ratio of -0.01 and a beta of 1.36. Cutera has a 1-year low of $0.09 and a 1-year high of $3.00.

Institutional Trading of Cutera

A hedge fund recently raised its stake in Cutera stock. Geode Capital Management LLC lifted its position in Cutera, Inc. (NASDAQ:CUTR) by 25.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 248,257 shares of the medical device company’s stock after purchasing an additional 50,046 shares during the quarter. Geode Capital Management LLC owned about 1.23% of Cutera worth $88,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 90.70% of the company’s stock.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.